Study: NCT01011166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo white opaque capsules taken by mouth from Day 1 to Day 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFN)
Description: Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFN)
Description: Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFN)
Description: Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFN)
Description: Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFN)
Description: Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFN)
Description: Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.